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The severity of attention-deﬁcit/hyperactivity disorder (ADHD) symptoms is a major predictor of long-term ADHD outcome.
To investigate if two-locus interactions might predict ADHD severity, we studied a sample of 1341 individuals from families
clustering ADHD, using the Vanderbilt Assessment Scale for Parents. Latent class cluster analysis was used to construct
symptom proﬁles and classify ADHD severity. Single nucleotide polymorphisms (SNPs) spanning ADHD-linked chromosomal
regions on chromosomes 4, 5, 10, 11, 12 and 17 were genotyped. SNPs associated with ADHD severity were identiﬁed and
potentialtwo-locusgeneticinteractionsweretested.WefoundthatSNPswithintheLPHN3geneinteractwithSNPsspanningthe
11q region that contains DRD2 and NCAM1 not only to increase the risk of developing ADHD but also to increase ADHD severity.
All these genes are identiﬁed to have a major role in shaping both brain development and function. These ﬁndings demonstrate
that genetic interactions may predict the severity of ADHD, which in turn may predict long-term ADHD outcome.
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Introduction
Attention-deﬁcit and hyperactivity disorder (ADHD) is one of
the most frequent psychiatric disorders in childhood, affecting
10% of children and adolescents in the United States.
1 ADHD
is characterized by elevated levels of inattention and/or
hyperactive or impulsive behaviors that cause signiﬁcant
impairment
2 on a child’s academic and social functioning.
3
Several studies show that the severity of ADHD symptoms
predicts long-term prognosis.
4–7 For example, Barry et al.
reported that the strongest predictor of discrepancy between
predicted achievement evaluated by measurements of
intellectual function and actual academic performance is the
severity of ADHD symptoms, deﬁned as the index composed
of averaged behavioral data obtained from the hyperactivity/
impulsivity checklist of DSM-IV, attention problems and
hyperactivity scores from the Behavior Assessment System
for Children-Parent Rating Scale, and from the total score on
the Home Situations Questionnaire.
4 Similar results have
been reported showing that the severity of inattention and
hyperactivity negatively correlates with academic perfor-
mance and has deleterious effects on other aspects related
to quality of life, such as risk avoidance and satisfaction.
5
Another study showed that ADHD severity was positively
associated with the use of tobacco, alcohol and marijuana.
6
In individuals without frank ADHD, higher levels of inattention
have been found to have a negative effect on both academic
performance and college adjustment.
7
Due to this evidence, using a clinical approach that takes
severity into account is relevant. Furthermore, the traditional
approach using the diagnostic criteria for ADHD as deﬁned in
the DSM-IV discards those individualswho, despite the severity
of some of the speciﬁc symptoms, do not ﬁt the overall numeric
criteria for the diagnosis of ADHD. However,the severity of their
symptoms could have a marked functional impact and these
individuals may beneﬁt from interventions.
8–10
In the etiology of ADHD, genetic factors are strongly
implicated.
11 Recently, we identiﬁed a common variant
of the Latrophilin 3 gene (LPHN3) that increases the risk of
developing ADHD by 1.2-fold. The ADHD population attribu-
table risk (PAR%) attributed to this gene is B9%, suggesting
that incidence of ADHD in the general population would be
reduced by about 9% if it were possible to control the effect of
the LPHN3 variant that confers susceptibility to ADHD.
12
Functional studies revealed that LPHN3 is expressed in key
brain regions related to attention and activity, and that its
variants affect metabolism in neural circuits implicated in
ADHD and are associated with response to stimulant
medication. These ﬁndings were replicated in samples
obtained from unrelated populations.
12,13 In addition to
increasing knowledge of the genetic basis of ADHD, the
discovery of the molecular substrates of ADHD opens up new
avenues for the exploration of targeted therapies.
In related studies, we analyzed two-locus interactions
models between LPHN3 variants on chromosome 4q and a
susceptibility haplotype on 11q encompassing the NCAM1,
TTC12, ANKK1 and DRD2 genes. The simultaneous pre-
sence of both genetic risk variants increases the risk of ADHD
by B2.5 compared with the risk when none of these variants
are present.
14 In addition to previous evidence linking these
two regions with human behavior,
15–20 we found that this
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www.nature.com/tpinteraction also explains differences in brain metabolism as
observed through proton magnetic resonance spectroscopy
(
1H-MRS) data and pharmacogenetic response to stimulant
medication better than the presence of either variant alone.
In the present study, we aimed to evaluate the hypothesis
thattheinteraction betweenADHD susceptibility factors on4q
and 11q, as well as other genomic regions, not only predicts
ADHD susceptibility but also the severity of the disease, as
ADHD severity is the best indicator of long-term outcome.
In this way, we additionally expand upon our previous ﬁndings
to place them in a context where they may have a greater
impact in terms of deﬁning interventions for affected and
subsyndromal individuals.
Subjects and methods
Subjects. We analyzed a total of 349 nuclear families
consisting of a total of 1371 individuals. Participants
were from a United States population, 4–65 years of age,
ascertained from ADHD probands. Diagnosis of ADHD in
children was established using the DSM-IV criteria;
2 in adults,
the Conners Adult ADHD Rating Scale (CAARS)
21 was used.
All participants were evaluated using the Vanderbilt
Assessment Scale for Parents (VAS-P),
22 which includes all
18 DSM-IV criteria for ADHD (questions 1–9 for inattention;
questions 10–18 for hyperactivity/impulsivity), oppositional
deﬁant disorder (ODD; questions 19–26), conduct disorder
(CD; questions 27–40) and seven items from the Pediatric
Behavior Scale
23 screening for anxiety and depression (A/D;
questions 41–47 in the VAS-P). Each question of the VAS-P
is scored based on the frequency of presentation of the
b e h a v i o ro na1t o4s c a l e( 1 ¼never, 2¼occasionally,
3¼often and 4¼very often).
22 Complete information was
available for 1341 individuals. More detailed information
regarding clinical assessment and speciﬁc demographics of
this sample is described elsewhere.
8
Deﬁnition of severity. Latent class cluster analysis (LCCA)
models containing 1–10 classes were ﬁtted to the data using
Latent GOLD 4.5 (Statistical Innovations, Belmont, MA,
USA). Latent GOLD uses both EM and Newton–Raphson
algorithms to ﬁnd the maximum likelihood for each model
after estimating model parameters.
24 In the LCC models,
separate analyses were performed for each of the ﬁve VAS-P
domains (inattention, hyperactivity, ODD, CD and A/D). The
number of clusters was selected using a likelihood ratio test
evaluating whether increases in likelihood (L
2) associated
with increased latent classes justiﬁed their inclusion.
Certainty of these clusters was assessed calculating
P-values associated with L
2 values after running 500
parametric bootstrap replicates. As covariates for all
models, we used gender, ADHD diagnosis and age as
categorical variables (children: 4–11 years; adolescents:
12–17 years; adults 417 years).
12
As implemented in Latent GOLD, individuals are assigned
posterior membership probabilities for belonging to each
cluster based on their symptom proﬁles. Individuals are
additionally assigned to the cluster for which the posterior
probability is highest. Based on this assignment, VAS-P
proﬁles are obtained for each cluster. Using these proﬁles,
a severity scale was derived as follows: consider the LCC
results for a particular VAS-P domain, for example, inatten-
tion, and let K be the number of clusters found, Q be the
number of questions in that domain, ni be the number of
individuals in that cluster (i¼1,2,y,K) and NP
i be the number
of questions in cluster i with an average proﬁle P.I fNP
i 4Q/2,
allniindividualsinclusteriwillbeclassiﬁedasbeingseverefor
this domain, and not severe otherwise. In other words,
individuals with severe symptoms will be those for whom the
cluster they belong to, has at least Q/2þ1 questions with a
proﬁle above ‘Ocassionally’. From now on, individuals with
severe symptoms will be treated as ‘cases’ and non-severely
affected individuals as ‘controls’. For the analyses, this
derivation allows more precise descriptions of each indivi-
dual’s characteristics (proﬁles), descriptions that would
be difﬁcult to deﬁne when relying solely on the categorical
DSM-IV diagnosis.
Genotyping and genetic statistical analysis. DNA was
prepared from peripheral-blood specimens and the Illumina
genotyping service was used for genotyping, as previously
described.
12 Out of the 1341 individuals who completed
the VAS-P questionnaire, blood samples were available for
1181; genetic data was available for 813 individuals. A total
of 369 markers homogenously distributed on genomic
regions of chromosomes 4 (156 markers), 5 (48 markers),
10 (7 markers), 11 (129 markers), 12 (15 markers) and 17
(14 markers), as described previously,
12 were selected for
analysis because of the presence of loci linked to ADHD in a
genetic isolate from Colombia.
25
Family-based association tests (FBATs) using a dominant
model under the hypotheses of no linkage and no association
were performed as implemented in Golden Helix’s PBAT
module (Golden Helix, Bozeman, MT, USA. Golden Helix
PBAT Software http://www.goldenhelix.com). These hypoth-
eses were selected because the linkage studies had been
performed on a different population, and hence there was no
previousknowledge about linkage or association in the United
States population described here. As phenotypes, the VAS-P
score, deﬁned as the summation of the individual’s responses
in a particular domain, and the VAS-P severity scale, derived
using LCCA, were used independently. The signiﬁcance of
markers was determined by using both the raw P-value and a
permutation-based approach with B¼10000 permutations.
Interactions effects on the severity of symptoms. We
used the generalized Cochran–Mantel–Haenszel test as
implemented in R,
26 to determine for all possible pairs of
markers located on different chromosomes and signiﬁcantly
associated either with the VAS-P score or the severity of
symptoms, whether the pair of single nucleotide
polymorphisms (SNPs) are independent, conditionally on
the levels of the severity phenotype (severe and not severe).
This approach was stratiﬁed by domain, and using the
deﬁnition of severity of symptoms previously described. A
total of p pairs of markers were found to be of potential
interest. By domain, the false discovery rate (FDR)
27 was
used to correct by multiple testing.
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particular domain we used the severity scale as the stratum
indicator, such that a series of p pairs of contingency tables,
each of dimension r c, can be obtained. In our context, p
(p¼587) is the number of possible pairs of markers located
within different chromosomes, r (r¼3) is the number of
possible genotypes in marker 1 and c (c¼3) the number of
possible genotypes in marker 2. To avoid any bias inherent to
family data, we selected only those families with (i) discordant
parents and concordant children affected, (ii) two discordant
siblings and unaffected parents, (iii) unaffected parents and
several discordant children and (iv) discordant parents and
discordant siblings. Families falling in the third case were
further examined so only one affected and one unaffected
Table 1 Summary of clusters derived by latent class analyses
Questions Criteria
a Cluster Characteristic and affection status for
broader phenotype
Predominant gender
and age classes
Severity of
symptoms
n (%)
Inattention
1–9 45 1 Minimal symptoms, unaffected for ADHD Females-adults Not severe 370 (27.6)
2 Few symptoms, unaffected for ADHD Males-adults Not severe 313 (23.4)
3 Mostly inattentive, high presence of symptoms,
affected for ADHD
Males-children and
adolescents (few adults)
Severe 271 (20.2)
4 Mostly inattentive, higher presence of
symptoms, affected for ADHD
Males-children and
adolescents (few adults)
Severe 182 (13.6)
5 Fewer symptoms, affected for ADHD Males-adults Severe 151 (11.3)
6 Fewer symptoms, affected for ADHD Males-children Severe 53 (4.0)
Hyperactivity/impulsivity
10–18 45 1 Minimal H/I symptoms, most individuals
unaffected for ADHD
Females-adults Not severe 418 (31.2)
2 Minimal H/I symptoms, most individuals
unaffected for ADHD
Males-adults Not severe 307 (22.9)
3 Few symptoms, affected for ADHD Males-adolescents Severe 165 (12.3)
4 High presence of symptoms except for Q12,
most individuals affected for ADHD
Males-children and
adolescents (few Adults)
Severe 165 (12.3)
5 Few symptoms for Q10–14 and fewer for
Q15-Q18, individuals are mostly affected
Females-adults Severe 101 (7.5)
6 Few symptoms for Q10 and Q11, but minimal
symptoms for the rest; ADHD affection status
is equally present
Males-all ages Not severe 58 (4.3)
7 Mostly H/I individuals, all affected for ADHD;
higher presence of symptoms
Males-children Severe 53 (4.0)
8 Mostly H/I individuals affected for ADHD;
high presence of symptoms
Males-children Severe 48 (3.6)
9 Few-to-minimalsymptomsexceptinQ15;ADHD
affection status is equally present
Males-children Not severe 25 (1.9)
ODD
19–26 43 1 Minimal symptoms, most individuals unaffected
for ADHD
Female-adults Not severe 365 (27.2)
2 Few symptoms, most individuals affected for
ADHD
Male-all ages Not severe 293 (21.9)
3 High presence of symptoms in Q19–25 and few
for Q26; most individuals affected for ADHD
Males-children Severe 182 (13.6)
4 Minimal symptoms in all questions; individuals
are mostly unaffected for ADHD
Males-adults Not severe 161 (12)
5 Minimal symptoms in all questions; ADHD
affection status is equally present
Males-children and
adolescents (few adults)
Not severe 149 (11.1)
6 Few symptoms in Q20 and Q24; ADHD affection
status is equally present
Females-adults Not severe 143 (10.7)
7 Higher presence of symptoms in all questions;
most individuals affected for ADHD
Males-children and
adolescents (few adults)
Severe 47 (3.5)
Anxiety and depression
41–47 42 1 Minimal symptoms in all questions; individuals
are mostly unaffected for ADHD
Males-adults Not severe 375 (28.0)
2 Fewer symptoms; mostly affected individuals Females-adults Not severe 376 (28.1)
3 Few symptoms; most individuals unaffected for
ADHD
Males-children Not severe 255 (19)
4 Fewer symptoms in Q41, Q42 and Q47 with few
on the rest; most individuals affected for ADHD
Males-children Not severe 157 (11.7)
5 High presence of symptoms; most individuals
affected for ADHD
Females-adults Severe 132 (9.9)
6 Higher presence of symptoms in all questions;
most individuals affected for ADHD
Females-adults Severe 45 (3.4)
Abbreviations: ADHD, attention deﬁcit hyperactivity disorder; adolescents, 12–17 years; adults, 417 years; children, 4–11 years; H/I, hyperactivity/impulsivity; ODD,
oppositional deﬁant disorder; Q, question.
aNumber of questions being marked as ‘often’ or ‘very often’ in the Vanderbilt Assessment Scale for Parents (VAS-P) questionnaire.
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gender and age range. Parents were excluded from families
falling in the fourth case. At the end of the process, only one
discordant pair was selected within those families that fulﬁlled
the inclusion criteria.
Results
Severity of ADHD symptoms. In our maximally expanded
sample (n¼1341), we identiﬁed six signiﬁcant independent
and mutually exclusive clusters for the VAS-P inattention
domain, nine for hyperactivity/impulsivity, seven for ODD and
six for the A/D (Table 1 and Figure 1), all of which were
consistent with ﬁndings from previous studies.
8,12,28–31
Because of small variability in the predictors in the CD
domain, LCCA models could not be ﬁtted to this data.
Individuals were considered as having severe symptoms
when belonging to clusters 3, 4, 5 and 6 in the inattention
domain (n¼647, 49%); to clusters 3, 4, 5, 7 and 8 in the
hyperactivity/impulsivity domain (n¼532, 39.7%); to clusters
3 and 7 in the ODD domain (n¼229, 17%) and to clusters 5
and 6 in the A/D domain (n¼177, 13.2%) (Figure 1). Under
this categorization, severe versus not severe status involves
all of the independent variation conferred by the spectrum of
symptoms that deﬁne ADHD and its comorbidities. Further,
using this categorization for each domain, we performed
association and interaction analyses for the severity
phenotype.
FBAT. Once the severity of symptoms for each of the four
VAS-P domains was identiﬁed, an FBAT was performed,
taking into account the complete family structure and the
severity status (severe and not severe) as disease indicator
(outcome). In complementary analyses, the overall VAS-P
score for each dimension was also used as the outcome for
the FBAT as a general indicator of severity.
Table 2 presents the FBAT results for both the LCCA-
derived severity status and the overall VAS-P score for each
domain. After permutation, a total of 38 genetic markers were
found to be signiﬁcantly associated either with the VAS-P
score or the severity of symptoms by dimension.
In the inattention domain, a total of eight markers were
found to be associated with either the LCCA-derived severity
status or the VAS-P score. When considering the VAS-P
score, signiﬁcant associated markers were identiﬁed within
LPHN3 (4q),NDFIP1 (5q), andDRD2 (11q) and TTC12(11q);
Figure 1 Proﬁle plots derived using latent class cluster analysis applied to attention-deﬁcit and hyperactivity disorder symptoms as measured by the Vanderbilt
Assessment Scale for Parents (VAS-P) questionnaire. For each domain, VAS-P symptoms proﬁles within clusters are shown in a scale from 1 to 4 (1¼never,
2¼occasionally, 3¼often and 4¼very often). Demographic characteristics for each cluster are shown in a scale from 0 to 1, representing the proportion of individuals from
thepopulationwithsuchcharacteristics.(a)Inattention(Q1–Q9):Q1:careless,inattentive;Q2:sustainsattentionpoorly;Q3:appearstonotlisten;Q4:poorfollowthrough;Q5:
disorganized; Q6: avoids/dislikes sustained mental effort; Q7: loses needed objects; Q8: easily distracted; and Q9: often forgetful. (b) Hyperactivity/impulsivity items ( Q10–
Q18): Q10: ﬁdgets or squirms; Q11: cannot stay seated; Q12 restless; Q13: loud; noisy; Q14: always ‘on the go’; Q15: talks excessively; Q16: blurts out; Q17: impatient; and
Q18: intrusive. (c) Oppositional deﬁant disorder (ODD; Q19–Q26): Q19: loses temper; Q20: argues with adults; Q21: deﬁes adults’ rules; Q22: annoys others; Q23: shifts
blames to others; Q24: touchy; Q25: angry/resentful; and Q26: vindictive. (d) Anxiety and depression (Q41–Q47): Q41: fearful, worried; Q42: fear of making mistakes; Q43:
feels useless; Q44: blames self; Q45; feels unloved; Q46: sad; and Q47: embarrassed.
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within NCAM1 (11q).
For hyperactivity/impulsivity, two markers within SLC6A3
(5p) were found to be associated with the VAS-P score and
three markers within NCAM1 were associated with the
severity of symptoms.
ForODD,fourmarkerswerefoundtobeassociatedwiththe
VAS-P score and four with the severity of symptoms. For the
former, three of the four markers are within LPHN3 and one is
within NCAM1. For the severity of symptoms, all signiﬁcant
markers are within LPHN3.
For CD, six markers were found to be associated with the
VAS-P score, three within LPHN3 and three within NCAM1.
In the A/D domain, a total of eight markers were found to be
associated with the VAS-P score and six with the severity of
symptoms. Among the markers found to be associated with
the VAS-P score, four are within LPHN3, two are within
NCAM1, one is within GNPDA1 and one is within TPH2 (12q).
Regarding severity of symptoms, a total of six markers were
found to be associated, four within NCAM1, one within
GNPDA1, and one at an intergenic region between NCAM1
and TTC12 on chromosome 11.
LPHN3 11q interaction. By domain, a total of 567 unique
pairs of markers located at different chromosomes were
tested for SNP SNP interactions. After breaking up the
family data using the strategy previously mentioned, the
number of severe (cases)/not severe (controls) pairs of
individuals available for analysis was 184 for the inattention
domain, 169 for hyperactivity/impulsivity, 104 for ODD and
Table2 RawandpermutedP-valuesfromfamily-basedassociationtestsusingtheVAS-Pscoreandtheseverityofsymptomsderivedusinglatentclassanalyses,as
qualitative and quantitative traits, respectively
Marker Gene Allele Frequency Effect Score Severity
Inattention H/I ODD CD A/D Inattention H/I ODD A/D
Chromosome 4
rs1947275 LPHN3 C 0.814 + 0.00819
a
rs2132074 LPHN3 G 0.618 + 0.0017
a
rs4552500 LPHN3 G 0.608 + 0.0031
b
rs13124636 LPHN3 G 0.046   0.0414
b
rs4860091 LPHN3 T 0.386 + 0.0054
b
rs335322 LPHN3 G 0.575 + 0.007
b
rs10015239 LPHN3 A 0.577 + 0.0098
b
rs35106420 LPHN3 G 0.985 + 0.0154
b
rs12646895 LPHN3 G 0.508 + 0.0019
b
rs1510920 LPHN3 C 0.061 + 0.0368
b
rs186750 LPHN3 A 0.243 + 0.0216
b
rs734644 LPHN3 T 0.271 + 0.0117
b
rs6813183 LPHN3 G 0.300 + 0.0114
b
rs6551670 LPHN3 A 0.300 + 0.0105
b
rs6551669 LPHN3 C 0.300 + 0.0105
b
Chromosome 5
rs249637 NDFIP1 G 0.074   0.0216
b
rs37022 SLC6A3 T 0.831 + 0.0052
a
rs250682 SLC6A3 C 0.798 + 0.0082
b
rs6596271 SLC25A48 G 0.042   0.0052
b
rs164080 GNPDA1 C 0.526 + 0.0015
b
Chromosome 11
rs10891551 DRD2 A 0.122 + 0.0253
b
rs719804 TTC12 G 0.223   0.0117
b
rs4938006 NCAM1/
TTC12
G 0.109 + 0.034
b 0.0106
a 0.0359
a,c
rs12799083 DRD2 C 0.031   0.0107
b
rs4245148 DRD2 T 0.122 + 0.0251
b
rs17596017 NCAM1 T 0.024   0.0191
b
rs1381246 BSX C 0.451   0.0057
b
rs652285 NCAM1 T 0.057 + 0.0097
b 0.0082
b 0.0214
b
rs675646 NCAM1 C 0.071 + 0.0107
b 0.0807
b 0.0105
a
rs649568 NCAM1 T 0.044 + 0.0171
b 0.0162
b
rs702966 PHRF1 C 0.276   0.0121
b
rs2574829 NCAM1 G 0.394 + 0.0084
b
rs11214521 NCAM1 G 0.035   0.0226
rs11214505 NCAM1 G 0.082   0.0292
rs1055076 TTC12 A 0.175 + 0.0343
rs12222469 NCAM1 A 0.035 + 0.0183
b
Chromosome 12
rs17722134 TPH2 G 0.029   0.0085
b
Chromosome 17
rs7208257 ARRB2 C 0.055 + 0.0164
b
Abbreviations: A/D, anxiety and depression; CD, conduct disorder; H/I, hyperactivity/impulsivity; ODD, oppositional deﬁant disorder; VAS-P, Vanderbilt Assessment
Scale for Parents. Nonsigniﬁcant P-values after B¼10,000 permutations are shown in italic. No correction for the number of questions interrogated was performed in
genetic association analyses.
aPermutated P-value o0.01.
bPermutated P-value o0.05.
cEffect on the severity towards opposite direction to the one described in the ‘effect’ column.
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Mantel–Haenszel tests after correcting by multiple testing
using the FDR. Regardless of the VAS-P domain being
considered, statistically signiﬁcant SNP SNP interactions
include markers within LPHN3 and within the region
containing NCAM1, DRD2 and TTC12 genes (Table 2 and
Figure 2).
For the inattention domain, the interaction between
rs1947275 and rs17596017 was found to be statistically
signiﬁcant (M
2¼33.163, PFDR corrected¼0.00067). In this
case, comparison of the genotypes distribution for these
markers between cases and controls showed that decreasing
the number of copies of the T allele in LPHN3 (from CT to CC
in rs1947275) yields a reduction of the number double
homozygous individuals for the C allele (marker
rs17596017) (Figure 2).
For the hyperactivity/impulsivity domain, in which the
interaction between rs35106420 and rs620291 was signiﬁ-
cant (M
2¼20.497, PFDR corrected¼0.02766), similar results
were obtained. For instance, when the G allele is present in
LPHN3 and the allele C in NCAM1 (while keeping the other
ﬁxed), the number of cases with a particular genotype
decreases when compared with the controls (Figure 2).
For ODD, two interactions were found to be statistically
signiﬁcant, one deﬁned by the markers rs995447 and
rs11214505 (M
2¼41.379, PFDR corrected¼0.00008), and
one by the markers rs734644 and rs620291 (M
2¼26.795,
PFDR corrected¼0.00196). In the former, the presence of one
copyoftheGalleleinNCAM1yieldsareductioninthenumber
of cases with two copies of the C allele in LPHN3 and an
increment of those with only one copy of it. In the latter,
regardless the number of copies of the T allele in LPHN3,
the number of cases with one or more copies of the C
allele in NCAM1 is greater than the number of controls
(Figure 2).
In the A/D domain, only the interaction between rs1510920
and rs4938006 was statistically signiﬁcant (M
2¼23.973,
PFDR corrected¼0.00655). For instance, when the one copy
of the C allele is present in NCAM1, it yields a reduction in the
number of cases with one or more copies of the A allele in
LPHN3 (Figure 2).
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Figure 2 Genotypic frequency distribution for pairs of single nucleotide
polymorphisms (SNPs) contributing to interaction effects and assessed by the
Cochran–Mantel–Haenszel test. Signiﬁcant interaction effects involve markers in
the LPHN3 gene and a region in 11q that harbors the NCAM1 and DRD2 genes.
Epistatic effects are depicted by changes in color that represent signiﬁcant
differences in genotypic distribution among severe (cases) vs not severe (controls)
individuals. In there, the genotypes for one marker are held ﬁxed whereas
genotypesontheothermarkervary. Inattention:(a)markersrs1947275harboredin
LPHN3 and rs17596017, in NCAM1, contribute to the severity of symptoms in this
domain (M
2¼33.163, FDR-corrected P-value o0.001); (b) markers rs1947275
harbored in LPHN3 and rs12799083, in DRD2, produce a signiﬁcant interacting
effect contributing to the severity of symptoms (M
2¼28.456, FDR-corrected
P-value o0.005). H/I: (c) markers rs35106420, in LPHN3, and rs620291, in
NCAM1, produce an interacting effect contributing to the severity of symptoms
(M
2¼20.497, FDR-corrected
* P-value o0.05). ODD: (d) markers rs995447, in
LPHN3, and rs11214505, in NCAM1, interact to modify the severity of symptoms
(M
2¼41.379, FDR-corrected P-value o0.0001); (e) rs734644, in LPHN3, and
rs4938006 produce an epistatic effect contributing to the severity of symptoms
(M
2¼26.795, FDR-corrected P-value o0.01). A/D: (f) markers rs1510920, in
LPHN3, and rs4938006 localized closest to NCAM1 in an intragenic region of
chromosome 11q, interact to modify the severity of symptoms (M
2¼41.379, FDR-
corrected P-value o0.0001). *FDR-corrected P-values calculated on the basis
of 567 independent tests, corresponding to the maximum number of SNP pairs
for each of the four domains of the VAS-P questionnaire from which the severity of
symptoms was derived. Abbreviations as in Figure 1.
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Wefoundthatseveralgeneticmarkersinteracttoincreasethe
severity of ADHD symptoms in our population. These
markers, distributed along ﬁve chromosomal regions that
have previously been linked to ADHD in a genetic isolate
from Colombia,
25 are harbored in genes that have a potential
role in the neurobiology of ADHD. In our sample, two
genetic interactions, LPHN3 NCAM1 and LPHN3 DRD2,
modiﬁed the severity of symptoms in ADHD. The former
modiﬁes the inattention, hyperactivity/impulsivity, ODD and
A/D symptoms in ADHD, the latter acts on the inattention
domain only.
Severity was estimated in our sample by two methods, one
usingthe overall VAS-P score, and the secondquantifying the
magnitude of inattention, hyperactivity/impulsivity, CD, ODD
andA/D symptoms usingLCC. Byusing this methodology, we
could include in the analysis all the clinical information from
the individuals regardless of their categorically diagnosed
status. This approach may have a more direct translation to
the clinical context, where severity of symptoms is a major
predictor of functional outcome.
Of special interest in our ﬁndings is the association and
interactions found in regions that harbor genes previously
described as being associated with ADHD, such as LPHN3
12
and DRD2,
20 as well as the novel interaction between LPHN3
and NCAM1 recently described by our group.
14 These genes
are expressed in areas of the brain that have highly related
roles, which makes them relevant candidates to explain the
type and severity of ADHD symptoms.
LPHN3 is a novel ﬁnding in association with ADHD. Our
group has recently described the association between a
speciﬁc LPHN3 haplotype and the increased risk of ADHD,
particularly related to a higher risk of behavioral problems
such as conduct disorder and substance use disorder.
12 In
this study, we found that the interaction of three genetic areas
highly related to neurodevelopmental aspects as well as
function of the reward system predicts severity of ADHD
symptoms. This is a very interesting observation that
deserves further replication in a bigger sample.
The region located in chromosome 11q23 includes the
NCAM1, TTC12, ANKK1 and DRD2 genes, all of which are
functionally linked to dopamine in the brain. Many association
studies of DRD2 and substance dependence, including
alcohol dependence and drug dependence have been
reported.
32,33
NCAM1 is expressed in all cell types in the nervous system,
where it promotes neuron–neuron and neuron–glia adhesion.
It is also involved in signal transduction and critical develop-
mental events such as migration and proliferation, neurite
outgrowth and fasciculation, synaptogenesis and synaptic
plasticity.
34,35 It has important roles in the development of the
pre-frontal cortex
19 as well as in the regulation of dopaminer-
gic pathways
15 and response to stress.
18
Ourpreviousresultsshowthattheassociationofthemarker
rs65511665 (harbored in the LPHN3 gene) is stronger in
families from the Paisa population, a genetic isolate in
Colombia that has a high prevalence of ADHD and a subtype
highly co-morbid with disruptive behaviors.
12,36 Furthermore,
the same marker is associated with response to stimulant
medication
12,36 and, more recently, an interaction between
this marker and an haplotype in 11q increases the risk of
developing ADHD B2.5-fold.
14 The present study expands
previous work by adding an additional clinically relevant
distinction. The role of NCAM1 in ADHD has not been
extensively evaluated. However, according to our current
ﬁndings, this gene and the genetic markers in its vicinity
deserve further evaluation in the context of the implications
that it may have in the clinical expression of ADHD symptoms.
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